Европейски съюз - естонски - EMA (European Medicines Agency)

takeda manufacturing austria ag - octocog alfa - hemofiilia a. - antihemorraagilised ained - verejooksu ravi ja profülaktika hemofiilia a patsientidel (kaasasündinud faktor viii puudulikkus). advate ei sisalda von willebrand tegur farmakoloogilised tõhus kogused ja ei ole seega näidustatud von willebrand haigus.

Естония - естонски - Ravimiamet

g.l. pharma gmbh - buprenorfiin+naloksoon - keelealune tablett - 4mg+1mg 49tk; 4mg+1mg 7tk; 4mg+1mg 56tk; 4mg+1mg 28tk

Естония - естонски - Ravimiamet

cipla europe nv - paratsetamool - kihisev tablett - 500mg 20tk; 500mg 12tk; 500mg 10tk; 500mg 16tk; 500mg 8tk; 500mg 24tk; 500mg 50tk; 500mg 32tk; 500mg 60tk

Естония - естонски - Ravimiamet

krka d.d. novo mesto - nifedipiin - toimeainet prolongeeritult vabastav tablett - 20mg 30tk

Естония - естонски - Ravimiamet

g.l. pharma gmbh - buprenorfiin+naloksoon - keelealune tablett - 8mg+2mg 56tk; 8mg+2mg 7tk; 8mg+2mg 28tk

Естония - естонски - Ravimiamet

g.l. pharma gmbh - buprenorfiin+naloksoon - keelealune tablett - 2mg+0,5mg 49tk; 2mg+0,5mg 56tk; 2mg+0,5mg 28tk

Естония - естонски - Ravimiamet

unimed pharma spol. s r.o. - olopatadiin - silmatilgad, lahus - 1mg 1ml 10ml 1tk; 1mg 1ml 5ml 3tk; 1mg 1ml 5ml 1tk

Европейски съюз - естонски - EMA (European Medicines Agency)

incyte biosciences distribution b.v. - ponatinib - leukemia, myeloid; leukemia, lymphoid - antineoplastic agents, protein kinase inhibitors - iclusig is indicated in adult patients withchronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (cml) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutationphiladelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutation. vt lõigud 4. 2 assessment of cardiovascular status prior to start of therapy and 4. 4 situations where an alternative treatment may be considered.

Европейски съюз - естонски - EMA (European Medicines Agency)

astrazeneca ab - ticagrelor - peripheral vascular diseases; acute coronary syndrome - antitrombootilised ained - possia, koos atsetüülsalitsüülhappega (ash), on näidustatud aterotrombootiliste juhtumite ennetamiseks täiskasvanud patsientidel, kellel on äge koronaarsündroom (ebastabiilne stenokardia, st-elevatsioonita müokardiinfarkt [nstemi] või st-elevatsiooniga müokardiinfarkt [stemi]); patsiendile meditsiiniliselt õnnestus, ja need, kes on koos perkutaanse koronaarse interventsiooni (pci) või koronaararterite šunteerimine (cabg).

Естония - естонски - Ravimiamet

sanofi-aventis estonia oÜ - valproehape - süstelahuse pulber ja lahusti - 400mg 4tk